AbbVie (NYSE:ABBV) Stock Gets Price Target Boost from Leerink Partners

AbbVie (NYSE:ABBV) had its price objective boosted by equities researchers at Leerink Partners from $309.00 to $342.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s target price would indicate a potential upside of 18.07% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Oppenheimer raised their target price on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Morgan Stanley lifted their price target on AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a research report on Monday. Sanford C. Bernstein reiterated a “market perform” rating and set a $275.00 price target on shares of AbbVie in a report on Monday. Finally, Rothschild & Co Redburn increased their price objective on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $293.29.

AbbVie Stock Performance

Shares of AbbVie stock traded down $5.22 on Monday, reaching $289.67. The stock had a trading volume of 5,404,959 shares, compared to its average volume of 6,324,456. The business’s 50-day moving average price is $269.35 and its two-hundred day moving average price is $237.23. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $298.74. The stock has a market cap of $511.78 billion, a P/E ratio of 49.72, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. AbbVie’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $1.86 EPS. As a group, equities analysts forecast that AbbVie will post 13.92 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of ABBV. Burk Holdings LLC acquired a new position in AbbVie in the second quarter worth about $30,000. Marquette Asset Management LLC grew its stake in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. Principia Wealth Advisory LLC grew its stake in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares during the period. IMG Wealth Management Inc. raised its holdings in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after buying an additional 153 shares in the last quarter. Finally, Tacita Capital Inc acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $42,000. Institutional investors own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s third-quarter revenue reached $17.4 billion, ahead of expectations, while earnings also surpassed estimates. Growth from immunology drugs Skyrizi and Rinvoq is more than offsetting Humira’s erosion, helping the company raise its 2026 revenue and adjusted earnings outlook. AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
• Positive Sentiment: Analysts responded to the results by raising their targets. Morgan Stanley increased its target to $346 and maintained an “overweight” rating; RBC raised its target to $330 with an “outperform” rating; and Canaccord Genuity and Cantor Fitzgerald lifted targets to $338 and $325, respectively. Analysts Increase Their Forecasts on AbbVie After Strong Q3 Results
• Positive Sentiment: The company increased its quarterly dividend by 5.2% to $1.82 per share, or $7.28 annualized. The higher payout reinforces AbbVie’s appeal to income-focused investors and signals management’s confidence in cash-flow generation.
• Positive Sentiment: Pipeline developments provide a longer-term growth opportunity. AbbVie’s experimental ABBV-466 nearly doubled Skyrizi’s Crohn’s disease remission rate in a Phase 2 study, potentially supporting a future follow-on blockbuster. AbbVie’s Next Blockbuster Is Hiding in a Two-Drug Crohn’s Combo
• Neutral Sentiment: Investors are assessing whether Skyrizi, Rinvoq, neuroscience products and pipeline candidates can sustain growth as AbbVie transitions away from its former Humira-driven revenue base. ABBV Q3 Earnings Call Highlights
• Negative Sentiment: Humira’s decline remains a structural headwind, while AbbVie’s elevated earnings multiple leaves less room for execution disappointments or slower growth. The stock’s recent decrease may therefore reflect profit-taking after its strong run, despite favorable fundamentals.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.